C. Lisanti

1.1k total citations · 1 hit paper
26 papers, 679 citations indexed

About

C. Lisanti is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. Lisanti has authored 26 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 10 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. Lisanti's work include Cancer Immunotherapy and Biomarkers (7 papers), Cancer Treatment and Pharmacology (6 papers) and Inflammatory Biomarkers in Disease Prognosis (5 papers). C. Lisanti is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Cancer Treatment and Pharmacology (6 papers) and Inflammatory Biomarkers in Disease Prognosis (5 papers). C. Lisanti collaborates with scholars based in Italy, United States and Argentina. C. Lisanti's co-authors include Rebecca Lamb, Michael P. Lisanti, Anthony Howell, Herbert B. Tanowitz, Ubaldo Martinez‐Outschoorn, Béla Ózsvári, Federica Sotgia, Fabio Puglisi, Paola Di Nardo and Debora Basile and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Oncotarget.

In The Last Decade

C. Lisanti

22 papers receiving 662 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease

2015 383 citations C. Lisanti et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Lisanti Italy	9	321	312	185	147	50	26	679
Zhiyi Liu China	11	319 1.0×	308 1.0×	137 0.7×	94 0.6×	40 0.8×	16	656
Michele Bartoletti Italy	14	135 0.4×	273 0.9×	111 0.6×	149 1.0×	25 0.5×	54	575
Louis W.C. Chow China	17	288 0.9×	606 1.9×	227 1.2×	151 1.0×	36 0.7×	48	1.1k
Bishnuhari Paudyal Japan	16	178 0.6×	178 0.6×	107 0.6×	160 1.1×	58 1.2×	25	757
Catherine R. Sears United States	13	434 1.4×	305 1.0×	162 0.9×	262 1.8×	41 0.8×	30	810
Neil Oronsky United States	12	219 0.7×	137 0.4×	97 0.5×	147 1.0×	30 0.6×	21	493
Emman Shubbar Sweden	11	297 0.9×	163 0.5×	120 0.6×	108 0.7×	49 1.0×	25	608
Chunyan Li China	15	225 0.7×	208 0.7×	81 0.4×	138 0.9×	36 0.7×	65	658
Ching-Wei Chang Taiwan	8	295 0.9×	605 1.9×	125 0.7×	238 1.6×	40 0.8×	8	917
Zongjuan Li China	16	384 1.2×	259 0.8×	182 1.0×	189 1.3×	61 1.2×	29	783

Countries citing papers authored by C. Lisanti

Since Specialization

Citations

This map shows the geographic impact of C. Lisanti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Lisanti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Lisanti more than expected).

Fields of papers citing papers by C. Lisanti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Lisanti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Lisanti. The network helps show where C. Lisanti may publish in the future.

Co-authorship network of co-authors of C. Lisanti

This figure shows the co-authorship network connecting the top 25 collaborators of C. Lisanti. A scholar is included among the top collaborators of C. Lisanti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Lisanti. C. Lisanti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lisanti, C., Silvia Bolzonello, Lucia Da Ros, et al.. (2025). Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report. Current Oncology. 32(11). 606–606.

Brisotto, Giulia, Marcella Montico, Matteo Turetta, et al.. (2023). Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects. Viruses. 15(6). 1276–1276. 2 indexed citations

Lisanti, C., Anna Costantini, Mattia Garutti, et al.. (2023). 458P Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey. Annals of Oncology. 34. S373–S374.

Polesel, Jerry, et al.. (2023). A Randomized Clinical Trial Investigating an Integrated Nursing Educational Program to Mitigate Chemotherapy-Induced Nausea and Vomiting in Cancer Patients: The NIV-EC Trial. Cancers. 15(21). 5174–5174.

Risi, Emanuela, C. Lisanti, Alessia Vignoli, et al.. (2022). Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients. Translational Oncology. 27. 101585–101585. 2 indexed citations

Nardo, Paola Di, C. Lisanti, Mattia Garutti, et al.. (2022). Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. Expert Opinion on Drug Safety. 21(11). 1341–1355. 65 indexed citations

Lisanti, C., Debora Basile, Silvio Ken Garattini, et al.. (2022). The SAFFO Study: Sex-Related Prognostic Role and Cut-Off Definition of Monocyte-to-Lymphocyte Ratio (MLR) in Metastatic Colorectal Cancer. Cancers. 15(1). 175–175. 9 indexed citations

Garattini, Silvio Ken, Debora Basile, Marta Bonotto, et al.. (2021). Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. Cancers. 13(14). 3504–3504. 7 indexed citations

Lisanti, C., Debora Basile, Elisa Bertoli, et al.. (2020). The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer. Journal of Geriatric Oncology. 11(8). 1268–1273. 9 indexed citations

10.

Pelizzari, Giacomo, Francesco Cortiula, Michele Bartoletti, et al.. (2020). Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs & Aging. 37(9). 677–689. 2 indexed citations

11.

Bonotto, Marta, Debora Basile, Lorenzo Gerratana, et al.. (2020). Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. Future Oncology. 16(27). 2059–2073. 2 indexed citations

12.

Basile, Debora, C. Lisanti, Maria Antonietta Pizzichetta, et al.. (2019). Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. Recent Patents on Anti-Cancer Drug Discovery. 14(3). 203–225. 1 indexed citations

13.

Basile, Debora, Paola Di Nardo, Carla Corvaja, et al.. (2019). Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers. 11(6). 857–857. 89 indexed citations

14.

Cortiula, Francesco, Giovanna De Maglio, Maria Giulia Cangi, et al.. (2019). Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. Annals of Translational Medicine. 7(1). 14–14. 8 indexed citations

15.

Borghi, María Orietta, Michele Bartoletti, Debora Basile, et al.. (2019). CACHEXIA AND MALNUTRITION IN CANCER PATIENTS: INFLAMMATION INDEXES EVALUATION AND NUTRITIONAL INTERVENTION. Nutrition. 65. 2–3. 1 indexed citations

16.

Bartoletti, Michele, Giacomo Pelizzari, Lorenzo Gerratana, et al.. (2019). Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).. Journal of Clinical Oncology. 37(15_suppl). 5564–5564. 1 indexed citations

17.

Pelizzari, Giacomo, Lorenzo Gerratana, Debora Basile, et al.. (2019). Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).. Journal of Clinical Oncology. 37(15_suppl). 577–577.

18.

Bonotto, Marta, Debora Basile, Lorenzo Gerratana, et al.. (2018). Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. The Breast. 40. 45–52. 6 indexed citations

19.

Pelizzari, Giacomo, Lorenzo Gerratana, Debora Basile, et al.. (2018). Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. Journal of Clinical Oncology. 36(15_suppl). e13079–e13079. 3 indexed citations

20.

Pelizzari, Giacomo, Lorenzo Gerratana, Debora Basile, et al.. (2018). A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients. Annals of Oncology. 29. viii96–viii96. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact